menu
    • menu
    [{"orgOrder":0,"company":"Eversana","sponsor":"Zosano Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Eversana \/ Zosano","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/ Zosano"},{"orgOrder":0,"company":"Eversana","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Maralixibat","moa":"IBAT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eversana \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eversana \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Eversana","sponsor":"Evoke Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Eversana \/ Eversana","highestDevelopmentStatusID":"12","companyTruncated":"Eversana \/ Eversana"},{"orgOrder":0,"company":"Eversana","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Immunology","graph2":"Approved","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Eversana \/ Humanigen","highestDevelopmentStatusID":"12","companyTruncated":"Eversana \/ Humanigen"},{"orgOrder":0,"company":"Eversana","sponsor":"OWP Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"IND Enabling","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eversana \/ EVERSANA","highestDevelopmentStatusID":"5","companyTruncated":"Eversana \/ EVERSANA"},{"orgOrder":0,"company":"Eversana","sponsor":"Accord BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Leuprolide Acetate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Eversana \/ Eversana","highestDevelopmentStatusID":"12","companyTruncated":"Eversana \/ Eversana"},{"orgOrder":0,"company":"Eversana","sponsor":"Xspray Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Dasatinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eversana \/ Xspray Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/ Xspray Pharma"},{"orgOrder":0,"company":"Eversana","sponsor":"Shorla Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nelarabine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eversana \/ Eversana","highestDevelopmentStatusID":"12","companyTruncated":"Eversana \/ Eversana"},{"orgOrder":0,"company":"Eversana","sponsor":"Yaral Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Diclofenac Epolamine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Eversana \/ Yaral Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eversana \/ Yaral Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Eversana

    Menu

    Eversana

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Yaral Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Yaral Pharma Partners With EVERSANA to Support the Commercialization of Its Expanding Generics Portfolio

                            Details : Under the partnership, EVERSANA will support the expansion of its portfolio of pain and endocrinology products in the U.S., including Flector (diclofenac epolamine), a topical prescription therapy for acute pain due to minor strains, sprains, and contusi...

                            Brand Name : Flector

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 22, 2023

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Yaral Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelarabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Shorla Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection for the Trea...

                            Details : Nelarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older.

                            Brand Name : Nelarabine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 16, 2023

                            Lead Product(s) : Nelarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Shorla Oncology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Xspray Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (X...

                            Details : Under the agreement, EVERSANA will support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc (dasatinib) for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL).

                            Brand Name : Dasynoc

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 24, 2023

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Xspray Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Accord BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Accord Bio and EVERSANA Announce Partnership to Support the Launch of CAMCEVI

                            Details : CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide for subcutaneous injection that comes in a pre-filled syringe with no mixing required. In an open-label, single-arm study of 137 adults who received 42mg of CAMCEVI on Day 0 and ...

                            Brand Name : Camcevi

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            June 29, 2022

                            Lead Product(s) : Leuprolide Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Accord BioPharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Recipient : OWP Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuro...

                            Details : Under the partnership OWP will launch and commercialize its oral liquid formulations for neuroscience disorders. OWP has also received IND for Lamotrigine in multiple therapies for epilepsy, schizophrenia, bipolar disorder, major depressive, anxiety diso...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 05, 2022

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Recipient : OWP Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the ...

                            Details : The partnership aims at making lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration (FDA) and subsequent BLA.

                            Brand Name : Humaneered

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 10, 2021

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metoclopramide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Recipient : Evoke Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Evoke and Eversana Announce Commercial Launch of Gimoti™

                            Details : Gimoti™ is a nasal spray launched for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Product launch provides healthcare providers a novel treatment approach for patients suffering from symptoms of acute and recurrent ...

                            Brand Name : Gimoti

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 26, 2020

                            Lead Product(s) : Metoclopramide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Recipient : Evoke Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maralixibat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Mirum Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixib...

                            Details : Mirum will utilize EVERSANA’s commercialization platform to provide integrated nationwide distribution, specialty pharmacy, patient services and Hub support for maralixibat, if approved.

                            Brand Name : LUM001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 15, 2020

                            Lead Product(s) : Maralixibat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Mirum Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Eversana

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zolmitriptan

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Zosano Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtr...

                            Details : Zosano and EVERSANA will utilize EVERSANA’s commercial execution expertise for marketing, market access, distribution, sales force deployment, reimbursement, and patient adherence support services. EVERSANA to commercialize and distribute Qtrypta™ in...

                            Brand Name : Qtrypta

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 06, 2020

                            Lead Product(s) : Zolmitriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Zosano Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth